SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.
Börse SIX Swiss Exchange Zürich
ISIN CH0012005267
  • Novartis
    Börse SIX Swiss Exchange Zürich
    ISIN CH0012005267 WKN: 904278
    Symbol NOVN.SW
  • Novartis
    Börse Börse München
    Symbol NOTA
    EUR
  • NOVARTIS AG-REG
    Börse Gettex System der Börse München
    Symbol NOT
    EUR
  • NOVARTIS AG-REG
    Börse Börse Düsseldorf
    Symbol NOT
    EUR
  • NOVARTIS AG-REG
    Börse Börse Stuttgart
    Symbol NOT
    EUR
  • NOVARTIS AG-REG
    Börse Börse München
    Symbol NOT
    EUR
  • NOVARTIS AG-REG
    Börse Börse Frankfurt
    Symbol NOT
    EUR
  • Novartis
    Börse Quotrix System der Börse Düsseldorf
    Symbol NOTA
    EUR
  • Novartis
    Börse Tradegate System der Deutsche Börse AG (60%)
    Symbol NOTA
    EUR
  • Novartis
    Börse Gettex System der Börse München
    Symbol NOTA
    EUR
  • NOVARTIS AG-REG
    Börse Quotrix System der Börse Düsseldorf
    Symbol NOT
    EUR
  • Novartis
    Börse Börse Düsseldorf
    Symbol NOTA
    EUR
  • Novartis
    Börse Börse Stuttgart
    Symbol NOTA
    EUR
  • NOVARTIS AG-REG
    Börse Tradegate System der Deutsche Börse AG (60%)
    Symbol NOT
    EUR
  • NOVARTIS AG-REG
    Börse Börse Berlin
    Symbol NOT
    EUR
  • NOVARTIS AG-REG
    Börse Börse Hamburg
    Symbol NOT
    EUR
  • Novartis
    Börse NYSE New York Stock Exchange
    ISIN US66987V1098 WKN: 907122
    Symbol NVS
    USD
  • ISIN CH0012005267 WKN: 904278
    Symbol NOVN
    USD
  • Novartis
    Börse BVMF
  • Novartis
    Börse London Stock Exchange
  • Symbol NOTA
  • Symbol NOTA
  • CHF
  • MXN
  • USD
  • Novartis
    Börse Bolsa de Comercio de Buenos Aires
ISIN CH0012005267
WKN 904278
Symbol NOVN.SW
Börse SIX Swiss Exchange Zürich Zeitzone: Europe/Berlin
Firmenname Novan, IncCEO: G. Kelly Martin
Marktkapitalisierung 88.696.186.389 (+- 105%)

Die einen sagen so, die anderen so... Es gibt 4 Datenquellen:

218.646.976 oder 63.057.299 oder 172.940.000.000 oder 181.563.041.280

Mitarbeiter 34.802 (+- 200%)

Die einen sagen so, die anderen so... Es gibt 3 Datenquellen:

23 oder 59 oder 104.323 Mitarbeiter

Anzahl Aktien 2.265.008.000
KGV 17.9
EBITDA -24.745.000
Buchwert 0.02

Zahlt eine jähliche Dividende von 3 CHF zuletzt am 04.03.2021 weitere Aktien mit Jahresdividende Übersicht

Die Dividendenrendite entspricht 3,50 % p. a. beim aktuellen Kurs von 78,77 CHF +0,12%  weitere Aktien mit 2-4% Dividendenrendite

Novartis underperformed den DAX um -52 % (+55 % Dividenden) vom 27.04.2012 bis 15.09.2021

Die letzten Quartalsergebnisse Erwarteter Gewinn je Aktie beim aktuellen Wert von 78,77 CHF +0,12% 

Analystenmeinungen

Übersicht

Letzte Communitymeinungen

Ein User hat Novartis abonniert.

Aktionärsstruktur der Novan, Inc

159 News & Informationen zur Novartis Aktie

  • Novartis Q2 2021 Earnings Preview (NYSE:NVS)
    seekingalpha.com

    Novartis Q2 2021 Earnings Preview (NYSE:NVS)

    Novartis (NYSE:NVS) is scheduled to announce Q2 earnings results on Wednesday, July 21st, before market open.The consensus EPS Estimate is $1.49 (+9.6% Y/Y) and the consensus…

  • Cathie Wood’s ARK Invest Sells Over 1.8 Million Shares of Pure Storage – 24
    247wallst.com

    Cathie Wood’s ARK Invest Sells Over 1.8 Million Shares of Pure Storage – 24

    One of Cathie Wood's Ark Invest funds sold over 1.8 million shares of Pure Storage on July 19.

  • Brookmont Capital Management Buys ViacomCBS Inc, Honeywell International Inc, NVIDIA Corp, Sells Novartis AG, Lowe's Inc
    gurufocus.com

    Brookmont Capital Management Buys ViacomCBS Inc, Honeywell International Inc, NVIDIA Corp, Sells Novartis AG, Lowe's Inc

    GuruFocus Article or News written by insider and the topic is about:

  • Novartis, Eli Lilly and AbbVie Top 5-Year New Drug Productivity List
    gurufocus.com

    Novartis, Eli Lilly and AbbVie Top 5-Year New Drug Productivity List

    GuruFocus Article or News written by Barry Cohen and the topic is about: Bristol-Myers is last with just 3 novel medicines brought to market

  • Regenerative Medicine Market Research Report 2021-2030: Emerging Economies are Key Opportunity Areas for Market Players
    prnewswire.com

    Regenerative Medicine Market Research Report 2021-2030: Emerging Economies are Key Opportunity Areas for Market Players

    /PRNewswire/ — The “Regenerative Medicine Market Research Report: By Type (Cell Therapy, Gene Therapy, Tissue Engineered Products), Application…

  • Regenerative Medicine Market Research Report 2021-2030: Emerging Economies are Key Opportunity Areas for Market Players
    markets.businessinsider.com

    Regenerative Medicine Market Research Report 2021-2030: Emerging Economies are Key Opportunity Areas for Market Players

    DUBLIN, July 16, 2021 /PRNewswire/ — The 'Regenerative Medicine Market Research Report: By Type (Cell Therapy, Gene Therapy, Tissue Engineered Pr…

  • Cathie Wood’s ARK Invest Sells Over 1.3 Million Shares of Opendoor Technologies – 24
    247wallst.com

    Cathie Wood’s ARK Invest Sells Over 1.3 Million Shares of Opendoor Technologies – 24

    One of Cathie Wood's Ark Invest funds sold over 1,300,000 shares of Opendoor Technologies on July 15.

  • Novartis to Buy AveXis in $8.7 Billion Deal
    gurufocus.com

    Novartis to Buy AveXis in $8.7 Billion Deal

    GuruFocus Article or News written by Sydnee Gatewood and the topic is about: Company strengthens its lead in the gene therapy space

  • 7 Companies Owned By Nestlé
    investopedia.com

    7 Companies Owned By Nestlé

    Nestlé deals include Gerber, Ralston Purina, Stouffer's, Atrium, Freshly, a Starbucks licensing deal, and the pending purchase of Bountiful brands.

  • Incyte Announces Positive Phase 3 REACH3 Study Data Published In NEJM For Ruxolitinib (Jakafi®) In Chronic Graft-Versus-Host Disease
    thestreet.com

    Incyte Announces Positive Phase 3 REACH3 Study Data Published In NEJM For Ruxolitinib (Jakafi®) In Chronic Graft-Versus-Host Disease

    Incyte (Nasdaq:INCY) today announced that positive data from the Phase 3 REACH3 study have been published in The New England Journal of Medicine (NEJM)

  • Global Single Photon Emission Computed Tomography (SPECT) Market to Reach $2.5 Billion by 2026
    prnewswire.com

    Global Single Photon Emission Computed Tomography (SPECT) Market to Reach $2.5 Billion by 2026

    /PRNewswire/ — A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled…

  • Non-opioid Pain Treatment Market Size to Grow at a CAGR of 16.8% from 2021 to 2030
    globenewswire.com

    Non-opioid Pain Treatment Market Size to Grow at a CAGR of 16.8% from 2021 to 2030

    The global non-opioid pain treatment market valued at USD 13,200.6 million in 2020, and it is projected to grow at a CAGR of 16.8 % during the forecast…

  • Non-opioid Pain Treatment Market Size to Grow at a CAGR of 16.8% from 2021 to 2030
    globenewswire.com

    Non-opioid Pain Treatment Market Size to Grow at a CAGR of 16.8% from 2021 to 2030

    The global non-opioid pain treatment market valued at USD 13,200.6 million in 2020, and it is projected to grow at a CAGR of 16.8 % during the forecast…

  • Non-opioid Pain Treatment Market Size to Grow at a CAGR of 16.8% from 2021 to 2030
    globenewswire.com

    Non-opioid Pain Treatment Market Size to Grow at a CAGR of 16.8% from 2021 to 2030

    The global non-opioid pain treatment market valued at USD 13,200.6 million in 2020, and it is projected to grow at a CAGR of 16.8 % during the forecast…

  • Non-opioid Pain Treatment Market Size to Grow at a CAGR of 16.8% from 2021 to 2030
    globenewswire.com

    Non-opioid Pain Treatment Market Size to Grow at a CAGR of 16.8% from 2021 to 2030

    The global non-opioid pain treatment market valued at USD 13,200.6 million in 2020, and it is projected to grow at a CAGR of 16.8 % during the forecast…

  • Non-opioid Pain Treatment Market Size to Grow at a CAGR of 16.8% from 2021 to 2030
    globenewswire.com

    Non-opioid Pain Treatment Market Size to Grow at a CAGR of 16.8% from 2021 to 2030

    The global non-opioid pain treatment market valued at USD 13,200.6 million in 2020, and it is projected to grow at a CAGR of 16.8 % during the forecast…

  • Non-opioid Pain Treatment Market Size to Grow at a CAGR of 16.8% from 2021 to 2030
    globenewswire.com

    Non-opioid Pain Treatment Market Size to Grow at a CAGR of 16.8% from 2021 to 2030

    The global non-opioid pain treatment market valued at USD 13,200.6 million in 2020, and it is projected to grow at a CAGR of 16.8 % during the forecast…

  • Non-opioid Pain Treatment Market Size to Grow at a CAGR of 16.8% from 2021 to 2030
    globenewswire.com

    Non-opioid Pain Treatment Market Size to Grow at a CAGR of 16.8% from 2021 to 2030

    The global non-opioid pain treatment market valued at USD 13,200.6 million in 2020, and it is projected to grow at a CAGR of 16.8 % during the forecast…

  • Central Nervous System Disorders Therapeutics Market |Type and Geography| Forecast and Analysis 2021-2025|Technavio
    prnewswire.com

    Central Nervous System Disorders Therapeutics Market |Type and Geography| Forecast and Analysis 2021-2025|Technavio

    /PRNewswire/ — Technavio has been monitoring the Center Nervous System Disorder Therapeutics Market and the market size is expected to reach a value of USD 24….

  • Alzheimer’s Drugs Market Report 2021-2028 | Size, Share, Growth, Trends, Competitive Landscape, Revenue, Forecast Report
    globenewswire.com

    Alzheimer’s Drugs Market Report 2021-2028 | Size, Share, Growth, Trends, Competitive Landscape, Revenue, Forecast Report

    Key Prominent Players Covered in the Alzheimer’s Drugs Market Research Report Are Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc., Eli Lilly and Company.,…

  • Small Cap Biotech Stocks Should Be On Your Watch List In 2021 & Here’s Why
    pennystocks.com

  • Global Human Growth Hormone Drugs Market to Reach $4 Billion by 2026
    prnewswire.com

    Global Human Growth Hormone Drugs Market to Reach $4 Billion by 2026

    /PRNewswire/ — A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled…

  • Europa ETF kaufen: Ist der Vanguard FTSE Developed Europe ex UK ETF ohne Großbritannien sinnvoll?
    etf-nachrichten.de

  • Immutep Quarterly Activities Report
    thestreet.com

    Immutep Quarterly Activities Report

    Immutep entered late-stage development in the newly validated LAG-3 space
    Data from 1st line NSCLC and 2nd line HNSCC presented at ASCO
    Efti to be

  • Cathie Wood’s ARK Invest Sells for 7
    247wallst.com

  • Valuation in Geriatric Medicines Market to Reach US$ 1142.8 Bn by 2027, Use in Managing Cardiovascular Diseases Spurs Growth: TMR
    prnewswire.com

    Valuation in Geriatric Medicines Market to Reach US$ 1142.8 Bn by 2027, Use in Managing Cardiovascular Diseases Spurs Growth: TMR

    /PRNewswire/ — Geriatrics care has made enormous strides over the past few decades. Rapidly aging populations notably in some emerging economies and developed…

  • Valuation In Geriatric Medicines Market To Reach US$ 1142.8 Bn By 2027, Use In Managing Cardiovascular Diseases Spurs Growth: TMR
    thestreet.com

    Valuation In Geriatric Medicines Market To Reach US$ 1142.8 Bn By 2027, Use In Managing Cardiovascular Diseases Spurs Growth: TMR

    ALBANY, N.Y., July 12, 2021 /PRNewswire/ — Geriatrics care has made enormous strides over the past few decades. Rapidly aging populations notably in some

  • Lannett : Launches Fluvastatin Sodium ER Tablets
    marketscreener.com

    Lannett : Launches Fluvastatin Sodium ER Tablets

    PHILADELPHIA, July 12, 2021 /PRNewswire/ — Lannett Company, Inc. today announced that it recently began marketing Fluvastatin Sodium Extended-release Tablets, 80 mg, a partnered product…. | July 12, 2021

  • Late-Stage Clinical Study Readouts Biotech Investors Should Watch
    fool.com

    Late-Stage Clinical Study Readouts Biotech Investors Should Watch

    Several drugmakers have important clinical trial updates on the way.

  • Cathie Wood’s ARK Invest Buys & Sells for 7
    247wallst.com

  • Active Pharmaceutical Ingredients Market Worth USD 312 Billion by 2028 at 6.2% CAGR - Report by Market Research Future (MRFR)
    globenewswire.com

    Active Pharmaceutical Ingredients Market Worth USD 312 Billion by 2028 at 6.2% CAGR – Report by Market Research Future (MRFR)

    Active Pharmaceutical Ingredients Market Insights and Industry Analysis by Type of Synthesis (Biotech and Synthetic), By Molecules (Large Molecule and…

  • Cathie Wood’s ARK Invest Sells for 7
    247wallst.com

  • Global Anticoagulants Market (2021 to 2026) - by Drug Class, Route of Administration and Geography
    markets.businessinsider.com

    Global Anticoagulants Market (2021 to 2026) – by Drug Class, Route of Administration and Geography

    DUBLIN, July 7, 2021 /PRNewswire/ — The 'Global Anticoagulants Market (2021-2026) by Drug Class, Route of Administration, Geography and the Impac…

  • Outlook On The Pulmonary Drugs Global Market To 2026 - Rising Prevalence Of Pulmonary Diseases Is Driving Growth
    thestreet.com

    Outlook On The Pulmonary Drugs Global Market To 2026 – Rising Prevalence Of Pulmonary Diseases Is Driving Growth

    DUBLIN, July 7, 2021 /PRNewswire/ — The “Global Pulmonary Drugs Market (2021-2026) by Drug Class, Indication, Distribution Channel, Geography, Competitive

  • Malaysia Nuclear Medicines Market to Garner $70.24 Million by 2028: Allied Market Research
    globenewswire.com

    Malaysia Nuclear Medicines Market to Garner $70.24 Million by 2028: Allied Market Research

    Rise in incidence of targeted population in Malaysia, surge in adoption of SPECT and PET scans, and increase in population of geriatric population in…

  • NOVARTIS AG : Goldman Sachs reaffirms its Buy rating
    marketscreener.com

    NOVARTIS AG : Goldman Sachs reaffirms its Buy rating

    Already positive, the research from Goldman Sachs and its analyst Keyur Parekh still consider the stock as a Buy opportunity. The target price has been lifted and is now set at CHF 110 compared to CHF… | July 7, 2021

  • NOVARTIS AG : JP Morgan remains a Sell rating
    marketscreener.com

    NOVARTIS AG : JP Morgan remains a Sell rating

    The analyst from JP Morgan, Richard Vosser, maintains his advice to sell. The target price continues to be set at CHF 80. | July 6, 2021

  • Worldwide End Stage Renal Disease Industry To 2026 - High Focus On Technology Presents Opportunities
    thestreet.com

    Worldwide End Stage Renal Disease Industry To 2026 – High Focus On Technology Presents Opportunities

    DUBLIN, July 5, 2021 /PRNewswire/ — The “Global End Stage Renal Disease Market (2021-2026) by Disease Type, Treatment Type, End-user, Geography, Competitive

  • Multicultural Organization Definition
    investopedia.com

    Multicultural Organization Definition

    A multicultural organization promotes diversity and inclusion among its employees and does not discriminate by race, sex, age, or any other ascribed characteristic.

Schreibe einen Kommentar

Wenn du schon einen Account hast, logge dich ein bevor du den Kommentar absendest.

Galue Account Vorteile
  • Battles

    Messe dich mit der Community in Battles.

  • Badges

    Erhalte Belohnungen für Kommentare, die der Community helfen.

  • Mehr Informationen für alle

    Poste Bilder oder Videos zu Themen und Unternehmen und helf dabei, dass Investoren ein kontroverseres Bild erhalten.

  • Kein Datenrisiko

    Du kannst jederzeit deinen Account löschen und gespeicherte Daten einsehen.

Portrait der Novartis Aktie

Das Unternehmen Novan, Inc aus Schweiz beschäftigt 34.802 Mitarbeiter und ist in den Bereichen Chemie & Pharma, Pharmazeutika, Medizinische Produkte / Medizintechnik, Biotechnologie, Pharma tätig.

Die Novartis Aktie hat inklusive der Dividendenausschüttungen seit dem 27.04.2012 eine Gesamtrendite von 132% erwirtschaftet

Das Unternehmen Novan, Inc ist in mehr als 80 ETFs enthalten und somit ein eher allgemein bekannter Wert. Der Spitzenreiter UBS ETF (CH) SMI® gewichtet Novartis mit 16,90% im ETF.

Es ist auch möglich über Anleihen zu investieren. Hier findest du alle Novartis Anleihen auf einen Blick.

Entdecke die 6 ETFs in denen Novan, Inc am höchsten gewichtet ist Insgesamt in 80 ETFs enthalten

Dir gefallen die Informationen zu Novartis?

Börsen-Artikel (Arbeitstitel) bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20€ wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:

Zur ING Diba

Dir gefallen die Informationen zu Novartis?

Börsen-Artikel (Arbeitstitel) bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Aktiendepot bei Trade Republic, mit dem du mit einem pauschalen Euro Ordergebühren Aktien kaufen kannst. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15€ von Trade Republic geschenkt:

Zu Trade Republic

Dir gefallen die Informationen zu Novartis?

Börsen-Artikel (Arbeitstitel) bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20€ und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:

Zur Comdirect

Dir gefallen die Informationen zu Novartis?

Börsen-Artikel (Arbeitstitel) bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, Österreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:

Zu BUX Zero